Why Is ALUMIS INC EQUITY (ALMS) Stock Up Today?

ALMS stock is up 10.77% at $10.49 in the current session following a flurry of analyst activity and new data from a key clinical trial. The stock opened with a modest 2.1% gap up and has since surged to a session high of $10.64. The move comes after the release of topline results from the Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus, which showed mixed outcomes. While the primary endpoint was not met, a robust response was observed in the IFNGS-high subgroup, offering potential for further development.

What Happened

Analyst coverage has been active in the past 36 hours, with several firms adjusting their price targets and ratings. Oppenheimer and Baird each lowered their price targets, while H.C. Wainwright upgraded the stock to Buy from Neutral. Meanwhile, Morgan Stanley and Wells Fargo also reduced their price targets following the lupus trial results. Despite these mixed signals, the stock has surged, suggesting investor optimism about the drug’s potential in specific subpopulations and its broader TYK2 inhibition platform.

The recent trial results have triggered a broader reassessment of the company’s pipeline. While the lupus data was disappointing, the observed response in the IFNGS-high subgroup has led some analysts to maintain a cautious bullish stance. The stock’s sharp rebound follows a steep decline of 57% in the prior session, which was attributed to the trial’s failure to meet its primary endpoint.

What The Data Shows

The stock has traded between $9.61 and $10.64 in the session, with volume reaching 2.3 million shares, 1.9 times the 3-month average. Over the past eight sessions, the stock has fallen 55.3% from $22.86 to $10.23. Recent insider transactions show multiple executives selling shares in early August, with total sales amounting to $534,000 in the last 90 days. Unusual options activity has also been noted, with $279,000 in call premium and $271,000 in put premium exchanged.

What To Watch

Investors should monitor the company’s next steps regarding the LUMUS trial and potential follow-up studies. No earnings date is scheduled in the near term, but coverage breadth and further analyst commentary will be key to tracking sentiment shifts.